STAT

JUNE 3, 2025

Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting across the Pharmalot campus, where the official mascots are foraging for their breakfast and rousing the neighbors. This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups of stimulation. Our choice today is banana split, which is fast becoming a trusty favorite.

Drug Pricing 198

Drug Pricing Labelling 198

PharmaVoice

JUNE 3, 2025

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

130

130

STAT

JUNE 3, 2025

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.  Sign up here. Good morning! It’s June 3 — a significant day in the fictional “Gilmore Girls” town of Stars Hollow, and just another day of June/late spring/Pride for those of us in the real world. But there’s plenty of news today, so let’s get into it.

194

194

PharmaVoice

JUNE 3, 2025

Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.

130

130

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

STAT

JUNE 3, 2025

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Morning! Today, STAT’s Matthew Herper chats with J&J’s R&D chief, we see the radiopharmaceutical Pluvicto being considered earlier for prostate cancer, and more.

Drug Pricing 157

Drug Pricing Drug Development 157

STAT

JUNE 3, 2025

Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. Good morning health tech readers!

164

164

pharmaphorum

JUNE 3, 2025

The FDA has rolled out its highly-touted generative AI tool, almost a month early, with a promise to reduce the time taken for regulatory reviews

89

89

The Pharmacist

JUNE 3, 2025

No new distance selling pharmacies (DSPs) will be allowed as of 23 June 2025, following regulatory changes within the community pharmacy sector. Changes to the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 laid before Parliament on Monday will mean no new applications for online pharmacies can be accepted or permitted from around […] The post Halt to new distance selling pharmacies appeared first on The Pharmacist.

Online Pharmacies 82

Online Pharmacies Community Pharmacies 82

Pharma Times

JUNE 3, 2025

Enter The 2025 PharmaTimes Clinical Researcher of the Year The Americas!

82

82

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

BioPharma Dive

JUNE 3, 2025

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate tumors that harbor mutations in genes beyond BRCA.

65

65

pharmaphorum

JUNE 3, 2025

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer.

66

66

Pharma Marketing Network

JUNE 3, 2025

In todays crowded digital landscape, pharmaceutical brands face an increasingly complex task: turning awareness into action. While visibility remains important, engagement and conversion are what drive outcomes. That’s where CTAs (calls to action) come into play. For pharma marketers navigating strict compliance standards and shifting patient behavior, CTAs are not just marketing toolsthey are essential strategic assets.

Dosage 59

Dosage Communication 59

FDA Law Blog: Biosimilars

JUNE 3, 2025

By Larry K. Houck We appreciate receiving feedback on our blog posts. We received a response to our post on the prescribing red flags indicating the likelihood of certain prescriptions filled by Walgreens pharmacies were invalid because they lacked a legitimate medical purpose or were not issued in the usual course of professional practice. Press Release, Walgreens Agrees To Pay Up to $350M for Illegally Filling Unlawful Opioid Prescriptions and Submitting False Claims, U.S.

Prescription Filling 59

Prescription Filling Controlled Substances 59

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Big Molecule Watch

JUNE 3, 2025

Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgens bone cancer drug XGEVA, used to prevent fractures in those with bone metastases from solid tumors or multiple myeloma and to treat rare conditions like unresectable giant cell tumors. Earlier this year, Samsung also received approval in Korea for a biosimilar to PROLIA, Amgens other denosumab product used to treat hormone-induced bone loss and postmenopausal osteoporosis.

Biosimilars 59

Biosimilars 59

European Pharmaceutical Review

JUNE 3, 2025

BioNTech SEandBristol Myers Squibb ( BMS )have agreed a collaboration to advance a bispecific antibody, setting the stage for a potential new standard of care in cancer. BMS will pay BioNTech $1.5 billion upfront and $2 billion total in non-contingent anniversary payments through 2028. As part of the deal, BioNTech is also eligible for up to $7.6 billion in additional milestones.

52

52

Pharmaceutical Technology

JUNE 3, 2025

First-in-human data for the trispecific antibody suggest a paradigm shift for the relapsed/refractory multiple myeloma space.

52

52

Pharma Marketing Network

JUNE 3, 2025

In the competitive landscape of digital advertising, re-engaging potential customers who have previously interacted with your brand is crucial. TAP Native offers a sophisticated retargeting solution tailored for healthcare marketers, ensuring your message resonates with the right audience at the right time. Table of Contents Understanding TAP Native’s Retargeting Approach Cost-Effective Strategies for Healthcare Marketers Seamless Integration and User-Friendly Interface Real-World Applica

Scheduling Appointments 52

Scheduling Appointments Pharmaceutical Companies Pharmaceutical Companies Hospitals 52

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharmaceutical Commerce

JUNE 3, 2025

Direct-to-consumer and direct-to-patient models are major contributors.

59

59

PharmaTech

JUNE 3, 2025

The grant encompasses $100,000 each from the Life Sciences Entrepreneurship Center and Berkeley SkyDeck, with SkyDeck having the option to invest an additional $100,000.

52

52

Pharmaceutical Technology

JUNE 3, 2025

SpyGlass Pharma has closed a Series D funding round, raising $75m to advance the company's drug delivery platform.

52

52

pharmaphorum

JUNE 3, 2025

Discover how linvoseltamab combination data is shaping the future of multiple myeloma treatment. Karen Rodriguez-Lorenc shares insights from ASCO25 on patient needs and oncology advancements.

52

52

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

Pharmaceutical Technology

JUNE 3, 2025

The FDA set a PDUFA date in late 2025 as ziftomenib led to significant disease response in patients with common subtype of AML.

52

52

Pharmacy Times

JUNE 3, 2025

Chip Hailey, a 74-year-old pharmacist with hemophilia B, shares how gene therapy has liberated him from decades of challenging treatment and restored his independence.

50

50

Pharmaceutical Technology

JUNE 3, 2025

Clinical data for Genmabs ADC Rina-S is mounting, as the pharma company plans more late-stage trials.

52

52

Pharmacy Times

JUNE 3, 2025

Amanda Gronniger, PharmD, CPh, BCCP discusses practical strategies pharmacists can use to improve cholesterol management, from lifestyle counseling to emerging therapies.

49

49

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.